Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA at EvergreenHealth

Below are some of the SCCA clinical trials now being offered for patients at SCCA at EvergreenHealth in Kirkland. If you have any questions about these or other trials, please contact the clinical trial coordinator at (425) 899-3337.

 

Targeted Therapies for Triple Negative Advanced Breast Cancer (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

Investigator: Jennifer Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00733408

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery (NSABP P-5)
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer

Investigator: Tanya Wahl, MD;   Conditions: Colon Cancer;    Status: Closed;   Study ID: NCT01011478

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627 - TS-102)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Investigator: William Harris;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01483027

MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating The Efficacy And Safety Of Folfiri + Mehd7945a Versus Folfiri + Cetuximab In Second Line In Patients With Kras Wild-Type Metastatic Colorectal Cancer

Investigator: Andrew Coveler, MD;   Conditions: Colorectal Cancer;    Status: Closed;   Study ID: NCT01652482

ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01620190

Zevalin for Newly Diagnosed Diffuse Large B-cell Lymphoma (FH 7779)
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy (SPI-ZEV-11-301)

Investigator: Ajay K. Gopal, MD;   Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma;    Status: Closed;   Study ID: NCT01510184

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Closed;   Study ID: NCT00918723

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01165112